Previous 10 | Next 10 |
NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Sichenzia Ross Ference LLP announced today that it represented Relmada Therapeutics, Inc. (NASDAQ: RLMD), a clinical stage company developing depression and central nervous system disease therapies, in the successful completion of an underwritten ...
NEW YORK , Dec. 9, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the closing of its previously announced underwritten public offering of 3...
Image Source: ZwavelStream Clinic Company Thesis Relmada Therapeutics ( RLMD ) has recently announced top-line Phase 2 data for its sole pipeline candidate REL-1017 under evaluation for major depressive disorder. At first glance, the data seems fantastic and appears to have surpassed...
Relmada Therapeutics (NASDAQ: RLMD ) has priced its public offering of 3,333,334 common shares at $30.00 per share, for expected gross proceeds of $100M. More news on: Relmada Therapeutics, Inc., Healthcare stocks news, Read more ...
NEW YORK , Dec. 3, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the pricing of an offering of 3,333,334 shares of its common stock at a public...
NEW YORK , Dec. 3, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced its intention to offer and sell shares of its common stock in an un...
InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...
NEW YORK , Oct. 17, 2019 /PRNewswire/ -- Relmada Therapeutics Inc. (NASDAQ: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system diseases, announced today that the Relmada team will ring the NASDAQ stock market opening bell tomorrow, Frid...
Relmada Therapeutics (NASDAQ: RLMD ) announces positive results from a Phase 2 clinical trial evaluating REL-1017 (dextromethadone) in adult patients with major depressive disorder (MDD) who have failed to respond adequately to as many as three prior courses of treatment with antide...
NEW YORK , Oct. 15, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today reported top-line data from REL-1017-202, a double-blind, placebo-controlled Phase 2 cl...
News, Short Squeeze, Breakout and More Instantly...
Relmada Therapeutics Inc. Company Name:
RLMD Stock Symbol:
OTCMKTS Market:
Relmada Therapeutics Inc. Website:
Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry PR Newswire CORAL GABLES, Fla. , June 18, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage b...
Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference PR Newswire CORAL GABLES, Fla. , June 10, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of t...
Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference PR Newswire CORAL GABLES, Fla. , June 3, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the cent...